Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Assessment of the Efficacy of Floretyrosine F 18 ([18F]FET) Positron Emission Tomography (PET) for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes

NCT07238322 is registered in ClinicalTrials.gov with Telix Pharmaceuticals (Innovations) Pty Limited as lead sponsor.

NCT NCT07238322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07238322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Assessment of the Efficacy of Floretyrosine F 18 ([18F]FET) Positron Emission Tomography (PET) for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Phase
Observational
Overall status
Completed
Start date
September 22, 2025
Completion date
January 23, 2026
Enrollment
253 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

brain neoplasms, glioma, retrospective study